The American Enterprise Institute (AEI) released its own plan for making improvements to the healthcare system, which included ideas such as premium support for Medicare, explained Joe Antos, PhD, the Wilson H. Taylor Scholar in Health Care and Retirement Policy at AEI.
Bringing up palliative care is inherently difficult for providers, because it means bringing up death and dying, said Toby C. Campbell, MD, MSCI, associate professor of medicine, hematology-oncology at the University of Wisconsin School of Medicine and Public Health.
According to Marilyn Tavenner, president and CEO of America’s Health Insurance Plans, consumer and provider education plays a large role in the healthcare system’s transition to alternative payment-models and value-based care. Affordability is the operative word, for which Tavenner expects to be insurers biggest challenge in the coming future.
Healthcare informatics have improved education programs and initiatives as patient data becomes more open. However, data should be more widely shared, especially between employers and clinical providers, in order to better eliminate barriers to care access, said Karen van Caulil, PhD, president and CEO of the Florida Health Care Coalition.
Consumers should be actively engaged with their health coverage, so they will not only be informed of fines that may incur if they do not enroll, but also so that they are also aware of any new plans for the coming year that may best fit them and their family, said Jennifer Sullivan, director of the Best Practices Institute at Enroll America.
Recently, McKesson Business Performance Services and Blue Cross Blue Shield of Arizona partnered to form ACO Partner, a shared savings program focused on improving outcomes and costs.
Since the implementation of the ACA, health plans have been moving towards more managed, narrower plans. In addition, Erica Hutchins Coe, partner and co-leader of Center for US Health System Reform at McKinsey & Company, said that she has seen a progression of younger, healthier adults moving into the marketplace.
Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center, discusses side effects seen with PD-1 and PD-L1 inhibitors as well as the recent USPSTF screening recommendations for breast cancer.
Being a physician as well as a leader of a health insurance plan has provided John Bennett, MD, FACC, FACP, president and CEO of CDPHP, with a unique perspective on rising drug costs.
There is no silver bullet when it comes to implementing policies to constrain drug prices, but a value-based price approach will be essential, said Steven Pearson, MD, MSc, FRCP, founder and president of the Institute for Clinical and Economic Review.
As the United States healthcare system moves to value-based care, there have been clear signs of progress when it comes to better aligning incentives, but affordability remains a hurdle that needs to be overcome, said Bernard J. Tyson, chairman and CEO of Kaiser Permanente.
Scottsdale Health Partners helps patients with social needs through a complex care coordination program and working with community resources like adult protective services or other city government branches, James Whitfill, MD, chief medical officer, explained at the National Association of ACOs Spring 2016 Conference.
It’s crucial for accountable care organizations to not only understand what value-based purchasing is, but for everyone to be on the same page as far as the expectations involved and what exactly it takes to get there, said Brian Marcotte, president and CEO of The National Business Group on Health.
The new Medicare Part B proposal from CMS has been controversial, and Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, understands both sides of the argument. While he appreciates CMS' dedication to innovation, the demonstration may drive up payer costs.
Karen Ignagni discusses taking over EmblemHealth and implementing a turnaround after the company experienced net losses of more than $485 million in 2014, as well as the healthcare industry's transition to value-based payment.
Julia Adler-Milstein, PhD, assistant professor at the School of Information and the School of Public Health at the University of Michigan, describes the challenges of data gathering, and ensuring not only that the data is accurate and complete, but that the patient can use that data and ultimately lead a healthier lifestyle with that knowledge.
The process for approving biosimilars has been moving slowly, but Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts, foresees them as having the potential to lower costs for the industry and hopes the approval process will pick up speed.
With only 3 medications FDA-approved to treat opioid addiction, patient access to these treatment options can be difficult, and each medication presents its own challenges, said Kelly J. Clark, MD, MBA, president elect of the American Society of Addiction Medicine.
As the name and meaning of specialty medications have grown over time, so too has the importance of these pharmaceuticals, said Steven D. Pearson, MD, MSc, president of the Institute for Clinical and Economic Review.
Since the implementation of ACA, Florida Blue’s enrollment plans have changed in that plan has expanded its outreach platforms and had to educate a larger audience of consumers, explained Anne Jessup, senior director of digital channels at Florida Blue.
The new accountable care organization (ACO) benchmarking rule changes it so ACOs aren't just competing against themselves and transitions so ACOs have to be better than others in their region, Farzad Mostashari, MD, chief executive officer of Aledade, explained at the National Association of ACOs Spring 2016 Conference.
In order to slow the rising costs of prescription drugs there has to be a greater emphasis on value-based payments, on transparency, and on the consumer, perhaps even with the government’s help, said John Bennett, MD, FACC, FACP, president and CEO of CDPHP.
Lonny Reisman, MD, CEO of HealthReveal, expects big data to help achieve the triple aim goals by combining disparate sources of rich and varied information.
High-deductible health plans have a role to play, but it's important that they aren't used in such a way as to create a disincentive of the use of a consumer's benefits, said Niteesh Choudhry, MD, PhD, associate professor of medicine at Harvard Medical School.
Having psychosocial support for patients with cancer, and for their family members, is critical, because patients often feel that their emotional needs are overlooked in busy clinics, said Sophia K. Smith, PhD, MSW, associate professor at the Duke School of Nursing.
High costs associated with specialty pharmacy will necessitate the evolution of a new specialized model to help ensure that patients are receiving the financial assistance they need and adhering to their treatment, according to Steve Miller, MD, senior vice president and chief medical officer of Express Scripts.
The bar is set very high in terms of the biosimilar requirement definition, and physicians who are hesitant about substituting biosimilars for treatment should not be worried about the perceived differences, according to Pamela S. Becker, MD, PhD, professor of medicine in the Division of Hematology at the University of Washington School of Medicine.
Defining value of a treatment can be complicated, but at the center of it is the need to include both long-term and short-term effects, said Steven Pearson, MD, MSc, FRCP, founder and president of the Institute for Clinical and Economic Review.
In order for providers to achieve balance between patients who want more direction and patients who want more autonomy, the healthcare industry must first find some measure of patient engagement, said Julia Adler-Milstein, PhD, assistant professor at the School of Information and the School of Public Health at the University of Michigan.
Telemedicine works well with diabetes because it is a condition that works with a lot of numbers and data, and physicians can look at that data remotely rather than requiring a face-to-face visit, explained David Brumley, MD, MBA, senior medical director at Tufts Health Plan.
